Cancer Immunotherapy Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

Spread the love

Overview and Scope
Cancer immunotherapy refers to a type of cancer therapy that strengthens your body’s defenses against the disease. Your body’s immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

Sizing and Forecast
The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $97.88 billion in 2023 to $110.91 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%.  The  growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditional therapy, growing r&d activities for the development of targeted diseases, increased effectivity and accuracy of newer therapies, growing recognition of the limitations of traditional cancer treatments.

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $175.39 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%.  The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research,  increasing emphasis on real-world evidence and patient outcomes in treatment decisions.

To access more details regarding this report, visit the link:

Segmentation & Regional Insights
The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics

North America was the largest region in the cancer immunotherapy market in 2023 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

Major Driver Impacting Market Growth
The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based European Commission’s Joint Research Centre, new cancer cases increased by 2.3% during the preceding two years, reaching 2.74 million in 2022. Similarly, cancer fatalities increased by 2.4% during the preceding two years. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.

Key Industry Players
Major companies operating in the cancer immunotherapy market report are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

The cancer immunotherapy market report table of contents includes:

1. Executive Summary
2. Cancer Immunotherapy Market Characteristics
3. Cancer Immunotherapy Market Trends And Strategies
4. Cancer Immunotherapy Market – Macro Economic Scenario
5. Global Cancer Immunotherapy Market Size and Growth
31. Global Cancer Immunotherapy Market Competitive Benchmarking
32. Global Cancer Immunotherapy Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Cancer Immunotherapy Market
34. Cancer Immunotherapy Market Future Outlook and Potential Analysis
35. Appendix
Related Reports:

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model:

Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →